Human Beta-defensin 1 in Vitiligo

NCT ID: NCT03832751

Last Updated: 2019-02-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-31

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is a need to know the role of human beta defensin-1 in vitiligo pathogenesis and the probability of finding newer and effective therapy for vitiligo in the future.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitiligo

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

vitiligo patients

Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy

Group Type EXPERIMENTAL

skin biopsy before and after NB-UVB phototherapy

Intervention Type OTHER

skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1

Healthy controls

Tissue levels of human beta-defensin 1 in healthy controls

Group Type ACTIVE_COMPARATOR

skin biopsy before and after NB-UVB phototherapy

Intervention Type OTHER

skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

skin biopsy before and after NB-UVB phototherapy

skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with non-segmental vitiligo.
* Both genders.
* Age more than 18 years old.
* New cases or cases not receiving any treatment for at least 3 months prior to the study.

Exclusion Criteria

* Universal or segmental vitiligo.
* Any contraindication to phototherapy treatment.
* History of autoimmune diseases or other systemic diseases.
* Any other skin disease.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Maha Fathy Elmasry

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Dermatology 12

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Epidermal Cell Transplantation in Vitiligo Skin
NCT01629979 COMPLETED PHASE2/PHASE3
IL35 Level in Vitiligo
NCT05980390 UNKNOWN
Vitiligo, New Treatment and Serum s100B
NCT06768840 RECRUITING PHASE2/PHASE3
Leucotrichia in Vitiligo
NCT03402633 COMPLETED